Back to top
more

ChromaDex (CDXC)

(Delayed Data from NSDQ)

$6.77 USD

6.77
988,022

-0.22 (-3.15%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $6.76 -0.01 (-0.15%) 4:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

ChromaDex (CDXC) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

ChromaDex (CDXC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 100% and 7.93%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex Gears Up to Report Q3 Earnings: Here's What to Expect

by Zacks Equity Research

On CDXC's third-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its marketed product Niagen and updates on the pipeline.

Are Medical Stocks Lagging ChromaDex (CDXC) This Year?

by Zacks Equity Research

Here is how ChromaDex (CDXC) and Bioventus (BVS) have performed compared to their sector so far this year.

Is ChromaDex (CDXC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how ChromaDex (CDXC) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Is Brainsway (BWAY) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Brainsway Ltd. Sponsored ADR (BWAY) and ChromaDex (CDXC) have performed compared to their sector so far this year.

ChromaDex (CDXC) Reports Break-Even Earnings for Q2

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 100% and 1.35%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Regeneron (REGN) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Regeneron (REGN) delivered earnings and revenue surprises of 9.37% and 4.84%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag

by Zacks Equity Research

ChromaDex (CDXC) rises 12% as the FDA grants the Orphan Drug Designation and the Rare Pediatric Disease Designation to its investigational candidate, NRC, to treat ataxia telangiectasia.

Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 136.36% and 15.33%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 25% and 4.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 39.62% and 100.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 40% and 16.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -0.77% and 20.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 59.88% and 165.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 33.33% and 0.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will ChromaDex (CDXC) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Vertex (VRTX) delivered earnings and revenue surprises of 6.52% and 0.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Down 9.6% in 4 Weeks, Here's Why ChromaDex (CDXC) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for ChromaDex (CDXC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Here's Why ChromaDex (CDXC) is Poised for a Turnaround After Losing 7.5% in 4 Weeks

by Zacks Equity Research

ChromaDex (CDXC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks.com featured highlights Oxford Industries, ChromaDex, UserTesting and TravelCenters of America

by Zacks Equity Research

Oxford Industries, ChromaDex, UserTesting and TravelCenters of America have been highlighted in this Screen of The Week article.

Vaishali Doshi headshot

Bet on These 4 Top-Performing Liquid Stocks for Solid Returns

by Vaishali Doshi

Here are four top-ranked liquid stocks, Oxford Industries (OXM), ChromaDex (CDXC), UserTesting (USER) and TravelCenters of America (TA), which investors can add to their portfolio for returns.